2seventy bio Inc.
(TSVT)
undefined
undefined%
At close: undefined
3.27
0.00%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company.
The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
2seventy bio Inc.
| Country | United States |
| IPO Date | Nov 3, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | William D. Baird III, M.B.A. |
Contact Details
Address: 60 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.2seventybio.com |
Stock Details
| Ticker Symbol | TSVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860782 |
| CUSIP Number | 901384107 |
| ISIN Number | US9013841070 |
| Employer ID | 86-3658454 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William D. Baird III, M.B.A. | Chief Executive Officer, President & Director |
| Victoria Eatwell | Chief Financial Officer |
| Jessica Snow | Senior Vice President of Quality and Head of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 4 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 4 | Filing |
| Sep 25, 2024 | 8-K | Current Report |
| Aug 16, 2024 | 4 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |